In light of our previous demonstration that LEDGF/p75 overexpression in PCa cells promoted resistance to DTX [18], the present study was conducted to determine if targeting LEDGF/p75 in chemoresistant PCa cells would re-sensitize these cells to the clinically relevant taxane drugs DTX and cabazitaxel (CBZ), which are the first and second line cytotoxic chemotherapeutic drugs, respectively, approved by the Food and Drug Administration (FDA) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [45, 46]. The gene discussed is PSIP1; the disease is posterior cortical atrophy.